Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

APLMS and Kitalys to Host Healthy Longevity in Hong Kong

The 2026 Asia-Pacific Healthy Longevity International Summit (APAC-LMIS) will take place in Hong Kong from October 1-4, 2026, organized by the Asia-Pacific Longevity Medicine Society (APLMS) in collaboration with The Kitalys Institute. This summit aims to gather over 2,000 leaders from various sectors including longevity medicine, geroscience, and digital health, positioning Hong Kong as a pivotal center for innovation in the longevity economy. The theme, “From Vision to Action in Healthy Longevity,” emphasizes the need to translate scientific advancements into practical health solutions.

The summit will feature pre-summit activities designed to foster high-impact collaboration, including the Global Top 10 Longevity Breakthrough Awards and executive training for longevity clinic leaders. The main event will focus on cross-sector collaboration among academia, healthcare providers, and policymakers to establish next-generation standards and investment pathways. A significant aspect will be the role of longevity clinics in clinical translation, integrating lifestyle medicine and AI-driven systems to facilitate personalized interventions. The organizers stress that the future of longevity medicine is about implementation at scale, aiming to connect research, clinical practice, and regulatory frameworks for real-world impact.

The implications for the field are substantial, as the summit is poised to become a flagship global platform for advancing healthy longevity initiatives across the Asia-Pacific region. This event will likely accelerate timelines for drug development and regulatory approval processes, fostering a collaborative environment that could redefine standards in longevity therapeutics. The involvement of diverse stakeholders will enhance the potential for innovative solutions and broaden the scope of clinical applications in longevity research.

Source: lifespan.io